Effects of H1-Antagonist on Cognition

Cognition Clinical Trial

Official title:

Effects of H1-Antagonist on Stages of Human Information Processing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00846950
• Other study ID #: 06-3-075
• Status: Completed
• Phase: N/A
• First received: February 17, 2009
• Last updated: February 18, 2009
• Start date: December 2006
• Est. completion date: May 2007

Study information

• Verified date: February 2009
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether histamine is involved in memory and specific processes in human cognition.

Description:

The neurotransmitter histamine appears to be involved in human cognitive performance. However, the exact role is very unclear. The role it plays in memory performance is highly disputed, as animal studies show decreased performance when the H1-receptor is blocked in the central nervous system while such findings in humans is scarce. To clarify the role of histamine in human memory and different processes in cognition, the effects of an H1-antagonist (dexchlorpheniramine) on memory, alertness and sensory and motor processes are measured. The study will be conducted according to a within subject cross-over design using healthy volunteers.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 18
• Est. completion date: May 2007
• Est. primary completion date: May 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Healthy as determined by a physician

Exclusion Criteria:

• present or history of any neurological of psychiatric disease

• present or history of any substance abuse

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Cognition

Intervention

Drug:
• dexchlorpheniramine, lorazepam

Locations

Country	Name	City	State
Netherlands	Faculty of Psychology and Neuroscience, Maastricht University	Maastricht	Limburg

Sponsors (1)

Lead Sponsor	Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	P300 latency and LRP onset latency		1.5 hours after treatment	No
Secondary	Words recalled		1.5 hours after treatment	No

External Links

•   webpage of the experimental psychopharmacology unit of the Maastricht University